Werlabs AB
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Werlabs AB - overview
Established
2013
Location
Stockholm, -, Sweden
Primary Industry
Healthcare
About
Werlabs AB is a health technology company based in Stockholm, Sweden, specializing in health screening services through advanced blood testing and medical analyses, fostering proactive health management among consumers. Founded in 2013 in Stockholm, Sweden, Werlabs AB offers health screening services through blood tests and analyses. The company raised SEK 36 million in Angel funding in December 2018, securing a total amount raised of SEK 36 million and achieving a current company valuation of SEK 171 million. The CEO of the company is Henrik Forsberg.
Werlabs primarily provides a comprehensive range of health screening services through blood tests, health questionnaires, and medical analyses. Their core offerings include tailored health check-ups focused on both women's and men's health, as well as specialized packages addressing hormonal changes, fertility assessments, and menopausal evaluations. These services are designed to help clients monitor their health over time, identify potential health risks, and receive personalized guidance from licensed medical professionals. Werlabs operates over 200 sample collection sites across Sweden, catering to individuals seeking proactive health management, and its client base includes both individual consumers and corporate clients, with services aimed at enhancing overall health awareness and preventive care.
In 2022, Werlabs reported revenue of SEK 11,163,930, with an EBITDA of SEK -2,373,727. 4. Werlabs AB is focusing on expanding its product offerings and market reach. The company is currently designing new health screening packages targeted for release in late 2023, which will include advanced testing options tailored to specific health concerns.
Additionally, Werlabs plans to expand its services beyond Sweden, with targeted markets including Norway and Denmark by 2025. The recent Angel funding of SEK 36 million will support these initiatives, allowing for the development of new products and the establishment of new collection sites in the targeted regions.
Current Investors
Heartcore Capital
Primary Industry
Healthcare
Sub Industries
Diagnostic, Medical & Imaging Laboratories
Website
www.werlabs.se
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Werlabs AB - timeline of key events
Werlabs AB - employee data
Werlabs AB - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Member of the Board | BM | ||||||
| Chairman of the Board, Investor | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.